An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor by Borazanci, Erkut, Korn, Ronald, Liang, Winnie S., Guarnieri, Carol, Haag, Susan, Snyder, Courtney, Hendrickson, Kristin, Caldwell, Lana, Von Hoff, Dan, Jameson, Gayle

Get full text

Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001 by Barrett, Michael T., Lenkiewicz, Elizabeth, Evers, Lisa, Holley, Tara, Aziz, Meraj, Kiefer, Jeffrey, Maitra, Anirban, Hidalgo, Manuel, Kumar, Rajesh, Hlavacek, William, Stites, Edward, Posner, Richard G., Ramanathan, Ramesh, Von Hoff, Dan D.

Get full text

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors by GERRITS, C. J. H, BURRIS, H, FIELDS, S, VON HOFF, D. D, VERWEIJ, J, SCHELLENS, J. H. M, ECKARDT, J. R, PLANTING, A. S. T, VAN DER BURG, M. E. L, RODRIGUEZ, G. I, LOOS, W. J, VAN BEURDEN, V, HUDSON, I

Get full text

Michel Clavel lecture by Von Hoff, Dan D.

Get full text

Abstract LB-61: Targeting cancer cell metabolism in pancreatic cancer: p53, a key regulator of glycolysis and a major factor deciding the outcome of targeting the Warburg effect by Rajeshkumar, N.V, Dutta, Prasanta, Kamphorst, Jurre, Le, Anne, Yabuuchi, Shinichi, de Wilde, Roeland F., Campbell, Nathaniel R., Oliveira, Elizabeth De, Jesus-Acosta, Ana De, Rabinowitz, Joshua, Laheru, Dan, Jain, Sanjay K., Hidalgo, Manuel, Thompson, Craig B., Von Hoff, Daniel D., Gillies, Robert J., Maitra, Anirban, Dang, Chi V.

Get full text